Sanofi has received European approval for the half unit reusable insulin pen called JuniorSTAR. The insulin pen is intended for patients with Type-1 diabetes between six and eighteen years old. The JuniorSTAR provides healthcare professionals greater dosing flexibility due to the half unit dosing increments and can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
The lightweight pen has a large display, can deliver between 1 to 30 units per injection and has a single-step dial back. The pen is sold in three different colors to provide additional flexibility and allow for differentiation of insulin. A survey conducted by Sanofi in Europe found that 81 percent of patients/parents and 86 percent of nurses agreed that it was easy to carry the pen daily due to its light weight. In addition, 98 percent of patients/parents and 94 percent of nurses agreed that the large display with legible numbering allowed for easy reading of dosage. Finally, 91 percent of patients/parents and 89 percent of nurses concurred that the device’s single-step dial back made dialing back easy, without any insulin leakage.
Sanofi has partnered with Haselmeier GmbH, Stuttgart, Germany, to manufacture the JuniorSTAR insulin pen.